Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in Combination With Anti-Neoplastic Agents in Non-Hodgkin Lymphoma
NCT05283720Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Jun 2022
- Primary completion
- Nov 2032
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 2 trial of epcoritamab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), sponsored by Genmab. Started Jun 2022; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05283720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283720.